Odyssey Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ODTX research report →
Range $30 – $44
Price Chart
About the company
Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis.
- CEO
- Gary D. Glick
- IPO
- 2026
- Employees
- 100
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on ODTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $938.75M
- P/E
- -7.11
- PEG
- -0.07
- P/S
- 0.00
- P/B
- 1.30
- EV/EBITDA
- -9.16
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 177.71%
- ROIC
- -20.66%
Latest fiscal year · YoY change
- Revenue
- $2.98M+0.0%
- Gross Profit
- $2.98M+0.0%
- Op Income
- $-161,156,000
- Net Income
- $-148,647,000+0.0%
- EPS
- $-5.39+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $29.05
- 52W Low
- $15.10
- 50D MA
- $22.55
- 200D MA
- $19.88
- Beta
- 1.43
- RSI (14)
- 36
- Avg Volume
- 274.77K
No earnings-call transcripts are available for ODTX yet.
- Free Float
- 55.9%
- Shares Outstanding
- 48.03M
- Float Shares
- 26.86M
of shares held by institutions
60 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 5.18M | ▲ 5.18M |
| Sr One Capital Management, LP | 3.79M | ▲ 3.79M |
| Tpg Gp A, LLC | 3.69M | ▲ 3.69M |
| Lightspeed Management Company, L.L.C. | 3.61M | ▲ 3.61M |
| Orbimed Advisors LLC | 3.00M | ▲ 3.00M |
| Sanofi | 1.99M | ▲ 1.99M |
| Deerfield Management Company, L.P. (Series C) | 1.05M | ▲ 1.05M |
| Sands Capital Ventures, LLC | 875.00K | ▲ 875.00K |
| Hhlr Advisors, Ltd. | 831.66K | ▲ 831.66K |
| General Catalyst Group Management, LLC | 810.27K | ▲ 810.27K |
| Affinity Asset Advisors, LLC | 766.35K | ▲ 766.35K |
| Adage Capital Partners Gp, L.L.C. | 725.00K | ▲ 725.00K |
Held by 73 ETFs
Biggest fund positions in ODTX by dollar value.
Our ODTX coverage
Recent articles, reports, and earnings notes.
No research on ODTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ODTX report →Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026
globenewswire.com · Oct 6
Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Stock Has Consensus Target Price of $35.75 According to Brokerages
defenseworld.net · Oct 5
Odyssey Therapeutics, Inc. (ODTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com · Sep 16
Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum
globenewswire.com · Sep 16
Odyssey Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com · Aug 26
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
gurufocus.com · Aug 6
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
prnewswire.com · Aug 6
Odyssey Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Aug 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.